Roche will report new data on important progress for people with advanced cancers at ASCO 2012
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1 to 5, 2012, in Chicago.
Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.
Merck total revenues increase 3.2% to € 2.6 billion
- Details
- Category: Merck Group
The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to € 2,564 million in the first quarter of 2011. Sales for the Group increased 3.5% to € 2,564 million in first quarter compared to € 2,478 million in the year-ago quarter.
Pfizer provides topline results from Phase 3 study of Torisel®
- Details
- Category: Pfizer
Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT® (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
GlaxoSmithKline to fully acquire Cellzome for £61 million
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash.
Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation today announced the expansion of its Together on Diabetes® initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients.
Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University's School of Life Sciences to identify and validate novel targets in oncology and immunoscience.
More Pharma News ...
- Statistically significant clinical phase III results of Lu AA21004
- GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
- Cancer Support Community launches national program to assist patients with cancer
- Roche reports positive study of RoACTEMRA given by subcutaneous injection
- Abbott to Acquire Action Pharma's Investigational Compound, AP214
- Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company
- GlaxoSmithKline and Yale University establish drug discovery collaboration